Manama: National Health Regulatory Authority has been approved the clinical trial of Enovid, the nasal spray for covid patients.
The approval was given at the end of the study after the concerned authorities in the Ministry of Health submitted a medical report regarding this.
The experiment is being conducted on volunteers with COVD and mild Symptoms. After completion of the clinical trial and further analysis, regular use of the spray will be permitted. The spray is for the prevention and treatment of people with mild symptoms. You can also buy it from pharmacies without a doctor’s prescription, NHRA said.
Canadian company Sano Tysons has developed the spray. Nitric oxide bacteria, funges, etc. contained in the spray is effective against viral infections. The spray kills the virus in the upper respiratory tract.
This will help prevent the virus from spreading to the lungs. Early treatment can reduce the severity of the virus. It is clear from the study that 95% of patients treated with spray get relief within the first 24 hours. And 99% of patients will get relief within 72 hours, the study found. No side effects were recorded.
